title: Dasatinib therapy can result in significant pulmonary toxicity.
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre (PMCC), East Melbourne, Victoria, Australia.
authors.forename: Maciek
authors.initials: M
authors.lastname: Tatarczuch
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre (PMCC), East Melbourne, Victoria, Australia.
authors.forename: Kate
authors.initials: K
authors.lastname: Burbury
authors.affiliation: Department of Cardiology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
authors.forename: Louise
authors.initials: L
authors.lastname: Creati
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre (PMCC), East Melbourne, Victoria, Australia.
authors.forename: Elchanan H
authors.initials: EH
authors.lastname: Januszewicz
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre (PMCC), East Melbourne, Victoria, Australia.
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D000069439:Dasatinib / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D000069439:Dasatinib